Bosutinib – related pleural effusion in patients with chronic myeloid leukemia

Click to increase image sizeClick to decrease image size

Declaration of interests

MB Yüzbaşıoğlu has no conflict of interest to declare. AE Eşkazan has received advisory board honoraria from Novartis, and Pfizer and he also received speaker bureau honoraria from Novartis, Bristol-Myers Squibb, and Pfizer outside the present study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

A reviewer on this manuscript has disclosed that they have received honoraria and speaker fees from Bristol-Myers Squibb and Pfizer Inc. All other peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.